We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?
Read MoreHide Full Article
Key Takeaways
AstraZeneca fell 7.4% in 3 months as the FDA delayed a camizestrant decision after an advisory vote.
AZN's Q1 2026 growth was driven by 16 blockbuster medicines and strong oncology demand.
AstraZeneca targets $80B revenues by 2030, with plans to launch 20 new medicines.
AstraZeneca (AZN - Free Report) stock has declined 7.4% in the past three months despite reporting strong first-quarter 2026 results. A key driver of the decline was a pipeline setback. In April, an FDA advisory committee voted against recommending AstraZeneca’s breast cancer drug candidate camizestrant. Subsequently, in May, the FDA announced it would delay its decision on the camizestrant NDA, adding further uncertainty around the program.
However, one-off pipeline setbacks like these should not form the basis of an investment decision. Let’s understand AZN’s strengths and weaknesses to better analyze how to play the stock amid the latest price decline.
AZN’s Strong Portfolio of Blockbuster Drugs
AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines.
The company now has 16 blockbuster medicines, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza (partnered with Merck [(MRK - Free Report) ]), Soliris and Ultomiris in its portfolio, with sales (product sales and alliance revenues) exceeding $1 billion. These drugs drove AstraZeneca’s 8% top-line growth and 5% core EPS at CER in the first quarter of 2026, backed by increasing demand trends. Almost every new product that has been launched in recent years has done well.
Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap also contributed to top-line growth. A key new drug, Baxfendy (baxdrostat), was approved for treatment-resistant hypertension in the United States in May 2026.
AZN Enjoys Strong Position in the Oncology Space
Oncology is AstraZeneca’s biggest segment. The segment contributes roughly 44% of total product sales and continues to be the company’s primary growth driver.
AstraZeneca’s oncology sales were $6.8 billion in the first quarter of 2026, up 16% at constant exchange rate (CER). The strong oncology performance was driven by robust demand for drugs like Tagrisso, MRK-partnered Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Key new cancer drugs in AstraZeneca’s portfolio are Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer, and Datroway, co-developed with partner Daiichi, also for HR+ HER2- breast cancer and EGFR-mutant non-small cell lung cancer (NSCLC). These drugs are also contributing to sales growth. Truqap has seen rapid uptake in the U.S. market since launch, with the ex-U.S. market expected to be a key contributor in future quarters. Datroway is seeing strong launch uptake trends.
AstraZeneca is working to strengthen its oncology product portfolio through label expansions of existing products and to advance its oncology pipeline candidates. AstraZeneca also possesses one of the deepest late-stage oncology pipelines in the industry. A key pipeline candidate, camizestrant, an oral SERD, is under review in the United States, the EU and some other countries for HR+ HER2- metastatic breast cancer.
Several Headwinds Hurting AZN’s Top Line
AstraZeneca faces its share of challenges. The loss of exclusivity of mature brands like Brilinta, Pulmicort and Soliris is hurting sales. Generic versions of one of the company's major drug, Farxiga, have been launched in the United Kingdom and some emerging markets. Farxiga lost exclusivity in the United States in April 2026 and its revenues are expected to decline in the United States, Japan and China in 2026.
China, though an important market for AstraZeneca, remains a somewhat uncertain market due to pricing pressure from volume-based procurement (VBP) programs and ongoing legal and compliance investigations involving the company’s former China head, Leon Wang. VBP-associated stock compensation costs hurt sales of Farxiga, Lynparza and roxadustat in China in the first quarter.
AZN Stock’s Price, Valuation & Estimates
AstraZeneca’s stock has declined 3.6% so far this year against an increase of 5.4% for the industry.
AZN Stock Underperforms Industry
Image Source: Zacks Investment Research
From a valuation standpoint, AstraZeneca is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 17.89 forward earnings, slightly higher than 17.80 for the industry. AZN’s stock is also trading above its 5-year mean of 17.49. The stock is, however, cheaper than other large drugmakers like Eli Lilly (LLY - Free Report) and J&J (JNJ - Free Report) .
AZN Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has declined from $10.29 per share to $9.39 per share over the past 60 days. For 2027, earnings estimates have declined from $11.53 per share to $10.52 per share over the same timeframe.
AZN Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in AZN Stock
AstraZeneca’s stock has declined this year, accompanied by downward revisions to earnings estimates. Despite the pullback, the shares still trade at a relatively rich valuation. In addition, several of the company’s established medicines are facing patent expirations and pricing pressures, creating uncertainty about whether revenues from these mature products can be replaced quickly enough by newer launches and pipeline candidates.
However, despite the headwinds, AZN expects continued revenue and earnings growth in 2026. It expects total revenues to grow by a mid-to-high single-digit percentage at CER in 2026, while core EPS is expected to increase by a low double-digit percentage at CER.
The company has also set itself some visible targets for the next few years. It expects to generate $80 billion in total revenues by 2030. By the said time frame, AstraZeneca plans to launch 20 new medicines, with around half of these already launched/approved. It believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. The company is also on track to achieve a mid-30s percentage core operating margin by 2026.
AstraZeneca’s pipeline is also strong, with pivotal data readouts lined up for 2026.
View the Zacks #1 Rank List
Image: Bigstock
AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?
Key Takeaways
AstraZeneca (AZN - Free Report) stock has declined 7.4% in the past three months despite reporting strong first-quarter 2026 results. A key driver of the decline was a pipeline setback. In April, an FDA advisory committee voted against recommending AstraZeneca’s breast cancer drug candidate camizestrant. Subsequently, in May, the FDA announced it would delay its decision on the camizestrant NDA, adding further uncertainty around the program.
However, one-off pipeline setbacks like these should not form the basis of an investment decision. Let’s understand AZN’s strengths and weaknesses to better analyze how to play the stock amid the latest price decline.
AZN’s Strong Portfolio of Blockbuster Drugs
AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines.
The company now has 16 blockbuster medicines, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza (partnered with Merck [(MRK - Free Report) ]), Soliris and Ultomiris in its portfolio, with sales (product sales and alliance revenues) exceeding $1 billion. These drugs drove AstraZeneca’s 8% top-line growth and 5% core EPS at CER in the first quarter of 2026, backed by increasing demand trends. Almost every new product that has been launched in recent years has done well.
Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap also contributed to top-line growth. A key new drug, Baxfendy (baxdrostat), was approved for treatment-resistant hypertension in the United States in May 2026.
AZN Enjoys Strong Position in the Oncology Space
Oncology is AstraZeneca’s biggest segment. The segment contributes roughly 44% of total product sales and continues to be the company’s primary growth driver.
AstraZeneca’s oncology sales were $6.8 billion in the first quarter of 2026, up 16% at constant exchange rate (CER). The strong oncology performance was driven by robust demand for drugs like Tagrisso, MRK-partnered Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Key new cancer drugs in AstraZeneca’s portfolio are Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer, and Datroway, co-developed with partner Daiichi, also for HR+ HER2- breast cancer and EGFR-mutant non-small cell lung cancer (NSCLC). These drugs are also contributing to sales growth. Truqap has seen rapid uptake in the U.S. market since launch, with the ex-U.S. market expected to be a key contributor in future quarters. Datroway is seeing strong launch uptake trends.
AstraZeneca is working to strengthen its oncology product portfolio through label expansions of existing products and to advance its oncology pipeline candidates. AstraZeneca also possesses one of the deepest late-stage oncology pipelines in the industry. A key pipeline candidate, camizestrant, an oral SERD, is under review in the United States, the EU and some other countries for HR+ HER2- metastatic breast cancer.
Several Headwinds Hurting AZN’s Top Line
AstraZeneca faces its share of challenges. The loss of exclusivity of mature brands like Brilinta, Pulmicort and Soliris is hurting sales. Generic versions of one of the company's major drug, Farxiga, have been launched in the United Kingdom and some emerging markets. Farxiga lost exclusivity in the United States in April 2026 and its revenues are expected to decline in the United States, Japan and China in 2026.
China, though an important market for AstraZeneca, remains a somewhat uncertain market due to pricing pressure from volume-based procurement (VBP) programs and ongoing legal and compliance investigations involving the company’s former China head, Leon Wang. VBP-associated stock compensation costs hurt sales of Farxiga, Lynparza and roxadustat in China in the first quarter.
AZN Stock’s Price, Valuation & Estimates
AstraZeneca’s stock has declined 3.6% so far this year against an increase of 5.4% for the industry.
AZN Stock Underperforms Industry
From a valuation standpoint, AstraZeneca is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 17.89 forward earnings, slightly higher than 17.80 for the industry. AZN’s stock is also trading above its 5-year mean of 17.49. The stock is, however, cheaper than other large drugmakers like Eli Lilly (LLY - Free Report) and J&J (JNJ - Free Report) .
AZN Stock Valuation
The Zacks Consensus Estimate for 2026 earnings has declined from $10.29 per share to $9.39 per share over the past 60 days. For 2027, earnings estimates have declined from $11.53 per share to $10.52 per share over the same timeframe.
AZN Estimate Movement
Stay Invested in AZN Stock
AstraZeneca’s stock has declined this year, accompanied by downward revisions to earnings estimates. Despite the pullback, the shares still trade at a relatively rich valuation. In addition, several of the company’s established medicines are facing patent expirations and pricing pressures, creating uncertainty about whether revenues from these mature products can be replaced quickly enough by newer launches and pipeline candidates.
However, despite the headwinds, AZN expects continued revenue and earnings growth in 2026. It expects total revenues to grow by a mid-to-high single-digit percentage at CER in 2026, while core EPS is expected to increase by a low double-digit percentage at CER.
The company has also set itself some visible targets for the next few years. It expects to generate $80 billion in total revenues by 2030. By the said time frame, AstraZeneca plans to launch 20 new medicines, with around half of these already launched/approved. It believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. The company is also on track to achieve a mid-30s percentage core operating margin by 2026.
AstraZeneca’s pipeline is also strong, with pivotal data readouts lined up for 2026.
Considering AZN’s growth prospects, one should stay invested in this Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.